RxDoctor Payments Data

Adebola Ajanaku

Psychiatric/Mental Health · Union, NJNPI 1669927224

Payments from drug & device makers

$2,905in general payments, 2019–2025

Across 167 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$763
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$487
  • Neurocrine Biosciences, Inc.$392
  • Supernus Pharmaceuticals, Inc.$352
  • Johnson & Johnson$207
  • Alkermes, Inc.$197
  • plus $507 from 6 others

What the payments were for

  • Food & beverage$2,905100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,905 in reported general payments places this provider in the 85th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$16,307
Medicare patients
31
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$35,367
Paliperidone ErPaliperidone16$6,880
Aripiprazole69$2,892
Clozapine22$2,512
Oxcarbazepine51$2,457
Quetiapine Fumarate149$1,242
Hydroxyzine Hcl114$1,223
Mirtazapine81$1,065
Sertraline Hcl195$929
Olanzapine65$909
Divalproex Sodium52$856
Alprazolam189$817
Risperidone101$742
Benztropine Mesylate57$585
Trazodone Hcl120$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$207$35,36712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Union

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →